Quick Answer: Wegovy and lisdexamfetamine can be prescribed together for their respective licensed indications, but require careful clinical assessment and close monitoring due to overlapping effects on appetite, cardiovascular parameters, and gastrointestinal function
Clinical trials indicate an average weight loss of around 15%, alongside improvements in metabolic parameters such as blood sugar control and blood pressure
By recognizing that obesity is a complex, chronic disease and not a lifestyle choice or a matter of willpower, we can help people find an integrated and personalized treatment approach that promotes long-term health and well-being, Neff adds
The randomized trial row states there is limited condition-specific data because most GLP-1 trials excluded patients with inflammatory bowel disease, and draws the implication that the safety profile in ulcerative colitis is simply unknown
Novo Nordisk funded the clinical trial
Likely yesbut with expert evidence and a clear timeline, attorneys can demonstrate that GLP-1 exposure, not weight loss alone, caused the injury